Komori
Business Alliance197ATAUNS Laboratories,Inc.Pharmaceuticals

Notice Regarding the Capital and Business Alliance with Asia Pathogenomics Co. Ltd.

タウンズ subscribed for common shares issued by Taiwan-based Asia Pathogenomics Co., Ltd. (APG) and entered into a capital and business alliance. The two companies will jointly develop an mNGS business for infectious diseases in Japan, while also expanding the NGS testing capabilities of タウンズ's clinical laboratory center.

Worth reading
66In focus
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Capital and Business Alliance
197ATAUNS Laboratories,Inc.
Alliance partner亞洲準譯股份有限公司 (Asia Pathogenomics Co., Ltd.)
Details of the alliance
  1. 1

    The company subscribed for common shares issued by APG

  2. 2

    Jointly develop a metagenomic next-generation sequencing (Metagenomic Next-Generation Sequencing, mNGS) business for infectious diseases in Japan

  3. 3

    Expand the NGS testing capabilities of Towns Clinical Lab

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionPathogen testing services
LocationNew Taipei City, Taiwan
Impact on Business Performance

At this time, we expect this basic agreement to have a limited impact on the company's near-term results. If it becomes clear that the agreement will have a material impact, we will disclose the information promptly.

Agreements reached under this partnership
ItemDetails
Name of alliance partner亞洲準譯股份有限公司 (Asia Pathogenomics Co., Ltd.)
Alliance partner's business activitiesPathogen testing services
Alliance partner's locationNew Taipei City, Taiwan
Type of allianceCapital and Business Alliance
Details of the allianceThe company subscribed for common shares issued by APG, Jointly develop a metagenomic next-generation sequencing (Metagenomic Next-Generation Sequencing, mNGS) business for infectious diseases in Japan, Expand the NGS testing capabilities of Towns Clinical Lab
Impact on Business PerformanceAt this time, we expect this basic agreement to have a limited impact on the company's near-term results. If it becomes clear that the agreement will have a material impact, we will disclose the information promptly.
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To accelerate the strengthening of タウンズ's outsourced testing business and the capabilities of Towns Clinical Lab, the company aims to leverage APG's technology, experience and track record to establish a next-generation outsourced testing services platform.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Capital and Business Alliance with Asia Pathogenomics Co. Ltd. | TAUNS Laboratories,Inc. (197A) timely disclosure | Komori